美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

335.54

+27.218.82%

盤後：334.80-0.7400-0.22%18:55 EDT

成交量：45.59萬

成交額：1.52億

市值：7.13億

市盈率：- -

高：340.20

開：317.82

低：317.82

收：308.33

52周最高：341.93

52周最低：66.95

股本：212.45萬

流通股本：212.45萬

量比：0.90

換手率：21.46%

股息：1.02

股息率：0.30%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

美國FDA代理局長呼籲對生菜保持信心並更新農產品安全指南

同和藥業(300636.SZ)：米拉貝隆原料藥獲得FDA註冊批准函DA註冊批准函

同和藥業：米拉貝隆原料藥獲FDA註冊批准函

人工智能公司Anthropic已告知部分投資者，該公司計劃進一步拓展醫療保健與生物學領域業務。

醫療板塊綜述：市場快評

醫療保健板塊動態：市場速評

Moderna美股盤前升逾2.4%，公司的mRNA流感疫苗獲得了美國FDA的正式批准上市，這是全球首款獲批的mRNA流感

醫療保健板塊市場動態速覽

遠大醫藥早盤升逾5% 自研GPN01530-2斬獲美國FDA快速通道資格

港股異動 | 遠大醫藥(00512)早盤升逾5% 自研GPN01530-2斬獲美國FDA快速通道資格

遠大醫藥：在研創新藥獲FDA快速通道認定

國產FAP核藥獲美國FDA加速審批通道遠大醫藥依託一體化核藥產業鏈角逐核藥市場

中國FAP靶向實體瘤診斷核藥首次獲FDA快速通道資格認定，遠大醫藥(00512)自研產品直擊泛實體瘤千億美元未滿足市場需求

遠大醫藥(00512.HK)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格

遠大醫藥(00512)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格

醫療保健板塊動態：市場快訊匯總

人民健康保險天津分公司被罰28萬，涉欺騙投保人

梁振英：在醫療健康領域香港也可成為「超級聯繫人」

醫療保健板塊市場快訊

醫療健康板塊綜述：市場動態快報

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrdive.com/hant/stock/LABU/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":335.54,"timestamp":1787688000000,"preClose":308.33,"halted":0,"volume":455921,"hourTrading":{"tag":"盘后","latestPrice":334.8,"preClose":335.54,"latestTime":"18:55 EDT","volume":1166,"amount":391135.78438,"timestamp":1787698515675,"change":-0.74,"changeRate":-0.002205,"amplitude":0.005961},"delay":0,"changeRate":0.08824960269840768,"floatShares":2124486,"shares":2124486,"eps":0,"marketStatus":"盤後交易","change":27.21,"latestTime":"08-25 19:01:33 EDT","open":317.82,"high":340.1999,"low":317.82,"amount":151598656.4468,"amplitude":0.072584,"askPrice":336,"askSize":1,"bidPrice":334.8,"bidSize":400,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787702400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":308.33,"sharesOutstanding":3074486,"nav":316.946,"aum":673347221.03,"dividendRate":0.003032,"bidAskSpread":0.002803,"preHourTrading":{"tag":"盘前","latestPrice":320.4,"preClose":308.33,"latestTime":"09:29 EDT","volume":4090,"amount":1297999.7005999999,"timestamp":1787664599999,"change":12.07,"changeRate":0.039146,"amplitude":0.037817},"postHourTrading":{"tag":"盘后","latestPrice":334.8,"preClose":335.54,"latestTime":"18:55 EDT","volume":1166,"amount":391135.78438,"timestamp":1787698515675,"change":-0.74,"changeRate":-0.002205,"amplitude":0.005961},"volumeRatio":0.904107,"impliedVol":0.9895,"impliedVolPercentile":0.7928},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":2124486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.904107,"shares":2124486,"dividePrice":1.0175,"high":340.1999,"amplitude":0.072584,"preClose":308.33,"low":317.82,"week52Low":66.95,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":335.54,"committee":0.995012,"eps":0,"divideRate":0.003032,"volume":455921,"delay":0,"ttmEps":0,"open":317.82,"prevYearClose":159.39,"prevWeekClose":317.2,"prevMonthClose":227.4,"prevQuarterClose":292.1,"fiveDayClose":289.98,"twentyDayClose":242,"sixtyDayClose":195.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658494167","title":"美國FDA代理局長呼籲對生菜保持信心 並更新農產品安全指南","url":"https://stock-news.laohu8.com/highlight/detail?id=2658494167","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658494167?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 07:29","pubTimestamp":1786490974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LABU","BK0016","000061","BK0210","BK4585","NBCM","COMT","BK0188","BK0027","BK0028","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658995180","title":"同和藥業(300636.SZ)：米拉貝隆原料藥獲得FDA註冊批准函DA註冊批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2658995180","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658995180?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 16:59","pubTimestamp":1786438775,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同和药业(300636.SZ)发布公告，公司于近日收到美国食品药品监督管理局(以下简称“FDA”)签发的米拉贝隆原料药注册批准函 DMF No Further Comments Letter(以下简称“NFC Letter”)。米拉贝隆是一种选择性β3-肾上腺受体激动剂，可通过激活膀胱逼尿肌上的β3-肾上腺受体而提高膀胱充盈和贮尿能力，临床用于治疗急迫性尿失禁、尿急、尿频等症状的膀胱过度活动症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","300636","BK4588","BK4585","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993147","title":"同和藥業：米拉貝隆原料藥獲FDA註冊批准函","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993147","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658993147?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 16:36","pubTimestamp":1786437370,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658963570","title":"人工智能公司Anthropic已告知部分投資者，該公司計劃進一步拓展醫療保健與生物學領域業務。","url":"https://stock-news.laohu8.com/highlight/detail?id=2658963570","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658963570?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 09:02","pubTimestamp":1786410136,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AIQU","TQQY","KOMP","QMAR","QQQM","LABU","NJAN","TARK","ARTY","NJUL","CPNQ","QLD","QQQ","SQQQ","CHAT","QDEC","QQA","XBI","GPIQ","CGVV","AQGX","XLV","NOBL","DQJN","FWD","07568","AIFD","NEWZ","TECY","VUSE","LCLG","QTOC","MFIG","NAPR","AGIX","CWC","QQQX","QSWN","NOCT","PSQ","QID","MVPS","VHT","NBDS","TQQQ","OGIG","GK","PBOT","WPAI","AIBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137780649","title":"醫療板塊綜述：市場快評","url":"https://stock-news.laohu8.com/highlight/detail?id=1137780649","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137780649?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 04:52","pubTimestamp":1786395164,"startTime":"0","endTime":"0","summary":"医疗板块最新市场快讯如约而至。本次快评内容聚焦于多家药企与医疗器械公司的动态，梳理了从晚期临床试验到财年业绩的各类关键信号。诺华股价当日微涨 0.3%。病理学服务提供商 Integral Diagnostics 的 2026 财年初步业绩，则令人失望。该公司预计年度营收在 7.88 亿至 7.90 亿澳元之间，低于市场普遍预期的 7.99 亿澳元。其运营息税折旧摊销前利润预计为 1.64 亿至 1.65 亿澳元，同样未能达到市场 1.69 亿澳元的预期。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","XLV","BK4581","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181671001","title":"醫療保健板塊動態：市場速評","url":"https://stock-news.laohu8.com/highlight/detail?id=1181671001","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181671001?lang=zh_tw&edition=fundamental","pubTime":"2026-08-11 00:22","pubTimestamp":1786378967,"startTime":"0","endTime":"0","summary":"最新的一轮医疗保健板块市场速评已出炉，信息发布时间分别为美国东部时间凌晨4:20、中午12:20及下午4:50。0339 EDT - 诺华旗下降胆固醇新药pelacarsen，其一项晚期试验的成功概率，如今正悬念重重。摩根大通认为，该药物达到这一门槛的可能性仅有40%。该公司预计全年营收在7.88亿至7.90亿澳元之间，远低于市场普遍预期的7.99亿澳元。在本周初，该机构对该股维持“跑赢大盘”评级，目标价为每股2.85澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","XBI","BK4588","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658263936","title":"Moderna美股盤前升逾2.4%，公司的mRNA流感疫苗獲得了美國FDA的正式批准上市，這是全球首款獲批的mRNA流感","url":"https://stock-news.laohu8.com/highlight/detail?id=2658263936","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658263936?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 20:25","pubTimestamp":1786364756,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4585","LABU","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124588838","title":"醫療保健板塊市場動態速覽","url":"https://stock-news.laohu8.com/highlight/detail?id=1124588838","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124588838?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 16:29","pubTimestamp":1786350589,"startTime":"0","endTime":"0","summary":"0729 GMT - 摩根大通分析师发布报告指出，诺华制药旗下降胆固醇药物pelacarsen的晚期试验前景尚不明朗。据摩根大通测算，这一结果发生的概率仅为40%。诺华股价微涨0.3%。该公司预计年度营收为7.88亿至7.90亿澳元，低于市场普遍预期的7.99亿澳元。其运营息税折旧摊销前利润预计为1.64亿至1.65亿澳元，也未达到市场预期的1.69亿澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","XBI","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658907609","title":"遠大醫藥早盤升逾5% 自研GPN01530-2斬獲美國FDA快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658907609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658907609?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 09:56","pubTimestamp":1786326974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660609","title":"港股異動 | 遠大醫藥(00512)早盤升逾5% 自研GPN01530-2斬獲美國FDA快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660609?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 09:44","pubTimestamp":1786326245,"startTime":"0","endTime":"0","summary":"消息面上，8月9日，远大医药发布公告，集团自主研发的用于诊断实体瘤的全球创新放射性核素偶联药物  GPN01530-2近日获得美国食品药品监督管理局授予的快速通道资格。FDA 设立快速通道机制，旨在加速和促进用于治疗当前并无有效治疗方案的严重或危及生命的疾病、且展示出有满足这一疾病当前未被满足的医疗需求潜力的新药的评审过程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477795.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1191","KCAI","LABU","00512","BK4588","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658775616","title":"遠大醫藥：在研創新藥獲FDA快速通道認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2658775616","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658775616?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 21:19","pubTimestamp":1786281568,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","MEDX","IBBQ","LNGR","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658672042","title":"國產FAP核藥獲美國FDA加速審批通道 遠大醫藥依託一體化核藥產業鏈角逐核藥市場","url":"https://stock-news.laohu8.com/highlight/detail?id=2658672042","media":"证券日报","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658672042?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 19:54","pubTimestamp":1786276440,"startTime":"0","endTime":"0","summary":"远大医药集团有限公司（以下简称“远大医药”）发布公告称，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格（FastTrackDesignation，FTD）。FTD资格主要授予用于治疗严重疾病且有潜力解决未满足医疗需求的在研药物，旨在加速高价值在研药物的审评进程。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835965072.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835965072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LABU","BK1191","BK4588","BK4585","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658728656","title":"中國FAP靶向實體瘤診斷核藥首次獲FDA快速通道資格認定，遠大醫藥(00512)自研產品直擊泛實體瘤千億美元未滿足市場需求","url":"https://stock-news.laohu8.com/highlight/detail?id=2658728656","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658728656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:18","pubTimestamp":1786270729,"startTime":"0","endTime":"0","summary":"作为核药龙头企业，远大医药近日在该领域再次取得重磅突破，公司FAP靶点创新核药GPN01530-2已获得美国FDA授予快速通道资格，成为全球首个获得FDA快速通道认定的实体瘤FAP靶点诊断核药。据悉，GPN01530-2此前已获FDA批准开展用于诊断实体瘤的I/II期临床研究，此次其获快速通道资格认定，标志着美国监管机构认可该产品在实体瘤诊断的重要潜力，有望加快GPN01530-2未来开发及上市进程，尽早惠及全球患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477702.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4588","BK4585","BK1191","00512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658367401","title":"遠大醫藥(00512.HK)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658367401","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658367401?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:10","pubTimestamp":1786270215,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658018674","title":"遠大醫藥(00512)自主研發的重磅全球創新放射性核素偶聯藥物GPN01530-2 獲得FDA授予的快速通道資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2658018674","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658018674?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 18:10","pubTimestamp":1786270215,"startTime":"0","endTime":"0","summary":"智通财经APP讯，远大医药 发布公告，集团自主研发的用于诊断实体瘤的全球创新放射性核素偶联药物  GPN01530-2 近日获得美国食品药品监督管理局授予的快速通道资格。GPN01530-2特异性靶向FAP为多种恶性肿瘤的诊断提供了新的可能。集团自主研发的GPN01530-2 优化了 FAP 配体的结构，提高了其在肿瘤组织中的摄取，同时降低其在正常组织中的摄取。据统计，全球放射性药物市场规模自2018年的50亿美元增至2024年的97亿美元，复合年增长率达 11.7%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","LABU","BK4585","00512","BK1593","BK4588","BK1583","BK1161","01530","HK0000165453.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131279132","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1131279132","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131279132?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 16:22","pubTimestamp":1786177346,"startTime":"0","endTime":"0","summary":"这些内容独家发布于道琼斯新闻社，分别在美东时间4:20、12:20和16:50。赛诺菲股价上涨2%，再生元股价则基本持平。第二季度调整后营业利润超出预期16%，主要得益于20亿丹麦克朗的回扣调整。该药企Wegovy药片的销售额略低于市场共识，而其美国注射剂销量则低于预期9%。花旗补充称，全年业绩指引上调已在预期之内，而CagriSema在与礼来替尔泊肽的头对头试验中失败，进一步打击了市场信心。该股上涨4.7%，报307.38克朗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","XLV","BK4588","LABU","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657276226","title":"人民健康保險天津分公司被罰28萬，涉欺騙投保人","url":"https://stock-news.laohu8.com/highlight/detail?id=2657276226","media":"蓝鲸财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657276226?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 14:22","pubTimestamp":1786170134,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月8日讯，近日，国家金融监督管理总局天津监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司天津分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司天津分公司的主要违法违规行为是：欺骗投保人。针对上述违法行为，国家金融监督管理总局天津监管局对中国人民健康保险股份有限公司天津分公司罚款28万元；对闻伟禁止终身进入保险业。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1786167414374667463","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK4581","LABU","XBI","BK4588","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657627583","title":"梁振英：在醫療健康領域香港也可成為「超級聯繫人」","url":"https://stock-news.laohu8.com/highlight/detail?id=2657627583","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657627583?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 13:17","pubTimestamp":1786166220,"startTime":"0","endTime":"0","summary":"梁振英表示，香港的价值定位是作为内地与其他国家之间的“超级联系人”。梁振英指出，如果把这套逻辑推演到医疗健康领域，未来香港完全有机会充当连接角色，搭建双向桥梁，对接全球供给与中国需求，同时对接中国供给与全球需求，这并非空想，而是长期目标，目前才刚刚起步。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-08-08/doc-inimqptv6574030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IXJ","159760","LABU","VHT","BK4550","XLV","XBI","BK4581","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183021512","title":"醫療保健板塊市場快訊","url":"https://stock-news.laohu8.com/highlight/detail?id=1183021512","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183021512?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 04:55","pubTimestamp":1786136134,"startTime":"0","endTime":"0","summary":"她认为该交易按当前方案完成的可能性为75%，但鉴于Jamieson的“优质资产”属性、在加拿大的领先市场份额，以及预计至2028年收入复合年增长率达11%，存在25%的可能性出现更高报价。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，但将评级从“买入”下调至“持有”。该股盘中上涨9.6%，报45.47加元。** 欧洲斯托克600指数上涨0.2%，软件和医疗保健板块领涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","XBI","BK4581","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145080185","title":"醫療健康板塊綜述：市場動態快報","url":"https://stock-news.laohu8.com/highlight/detail?id=1145080185","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145080185?lang=zh_tw&edition=fundamental","pubTime":"2026-08-08 00:23","pubTimestamp":1786119809,"startTime":"0","endTime":"0","summary":"她在报告中坦言，“对报价未达预期感到惊讶”。该分析师认为，按当前方案完成交易的概率为75%，但同时存在25%的可能性，因Jamieson具备“优质资产”属性、在加拿大市场占据领先份额，且预计至2028年收入复合年增长率达11%，报价有望被上调。消息公布后，TD将目标股价从48加元上调至49加元，以反映概率加权结果，同时将评级从“买入”下调至“持有”。该股现涨9.6%，报45.47加元。泛欧斯托克600指数上涨0.2%，软件与医疗健康板块领涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","XBI","BK4588","BK4585","BK4581","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}